Articles from Real Chemistry

Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare industry, continues to strengthen its media capabilities by acquiring Spring & Bond. A digital media agency known for its omnichannel-first approach and data-driven solutions, Spring & Bond is focused exclusively on healthcare, working with leading healthcare clients.

Real Chemistry, a leader in AI-driven insights and marketing communications exclusively for the healthcare sector, announces Meenakshi Yadav as Chief AI Products and Solutions Officer, marking a strategic leap in its AI journey.

Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, today announced the launch of HealthGEO – an AI search solution purpose-built for life sciences communicators and marketers, helping teams monitor, manage, and shape how AI search frames their science, story, and reputation.

Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, today announced it has acquired Greater Than One, an award-winning agency specializing in healthcare-first media, technology and omnichannel strategy. The acquisition brings expanded precision, stronger performance analytics and greater strategic clarity to Real Chemistry clients along every step of the commercialization journey.

Real Chemistry, a global leader in healthcare marketing and communications, today announced three strategic leadership appointments as part of the company’s ongoing commitment to attract transformative talent to fuel growth, spark innovation and redefine what’s possible for clients across healthcare’s dynamic ecosystem.

Real Chemistry continued its rise as a global creative leader in health, earning a Gold Pharma Lion at the 2025 Cannes Lions International Festival of Creativity for Biogen’s “Friedreich’s Back” campaign developed by 21GRAMS, part of Real Chemistry.

Real Chemistry today unveiled its 2024 business results and milestone achievements, cementing its role as a go-to medical marketing and communications partner for the most innovative healthcare companies and the top destination for the industry’s best and brightest talent.

Real Chemistry, a global leader in healthcare marketing and communications, today announced two strategic leadership moves to strengthen its presence in Europe. Camilla Griffiths has been appointed President, 21GRAMS Europe, bringing her extensive expertise in healthcare advertising and marketing strategy to accelerate the agency’s growth across the region. In parallel, Mike Nelson, President, Integrated Communications, has relocated from the U.S. to London to drive international client development.

Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, today announced the appointment of Jeff Lupinacci as Chief Financial Officer and Julia Gaebler, Ph.D., as President, Market Access. These strategic hires underscore Real Chemistry's commitment to driving innovation and meeting the evolving needs of its clients.

Real Chemistry, a leader in integrated healthcare marketing and advertising, today launched ROOM42, a centralized internal production hub aimed at revolutionizing the intersection between creative collaboration and production efficiency.

Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, announced today a partnership with Corval. The new partnership will introduce Real Chemistry clients to a new commercialization planning and launch platform designed to enhance efficiency and strategic alignment for biopharma companies. This proprietary platform is an added offering to Real Chemistry's comprehensive suite of solutions for the biopharma sector, and aims to streamline the commercialization planning process and integrate the support needed, enabling companies to accelerate their go-to-market strategies and achieve commercial success.

IRIS by Real Chemistry today released its second market-view report, “From Cost to Value: The Economic Impacts of GLP-1 Agonists on U.S. Healthcare.” The immersive report highlights the growing economic impacts of obesity and the GLP-1 agonist market on the U.S. healthcare system. The forecast predicts that the increase in uptake of these medicines will require the U.S. healthcare system to develop innovative financial models to treat obesity over the short and long-term.

Real Chemistry, a leading provider of AI-driven insights, healthcare marketing and communications, released a report on how the healthcare industry can more effectively use social media to promote early cancer screenings in young adults. The report features insights-informed strategies and recommendations for how healthcare companies can engage in important conversations around early cancer screenings. The report covers how early cancer screenings can lead to better patient outcomes, access to care and human-centric research, development and innovation.

Real Chemistry, a leading provider of AI-driven insights, marketing and communications for the healthcare industry, today announced three key leadership appointments that will help fuel organizational growth, expand the company’s future-forward analytics and insights solution pipeline, and add to the company’s expertise in paid media. These appointments underscore Real Chemistry's commitment to bring the best healthcare, technology and client-relationship experts to serve its clients.

Real Chemistry, a leading provider of AI-driven insights and marketing and communications for the healthcare industry, has launched IRIS – the only insights-as-a-service platform focused on helping healthcare leaders and other stakeholders act with clarity and confidence when transformative healthcare market events emerge. Fueled by the analysis of billions of data points using Real Chemistry’s proprietary AI, analytics and insights tools, IRIS offers a live dashboard and timely market reports. The reports provide a comprehensive, cross-functional analysis and insights into what's happening now in the healthcare market and the forces that could shape what's coming next; including its first detailed view of the fast-moving GLP-1 agonist obesity market.

Real Chemistry, a leading provider of AI-driven insights and marketing and communications for the healthcare industry, today reported financial results for the fiscal year ending December 31, 2023. The company achieved revenue of $595 million compared to $555 million in 2022, a 7% increase in year-over-year revenue.

Real Chemistry, a leading provider of AI-driven insights and marketing and medical communications for the healthcare industry, today announced significant expansion of its medical education, medical affairs and healthcare provider (HCP) communications capabilities through the addition of Avant Healthcare. Financial terms of the acquisition, which closed on Feb. 1, were not disclosed.

Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, today announced the expansion of its European presence with the addition of four new leaders and the opening of a second UK-based office in Manchester. These new leaders will build on the continued global growth and award-winning work achieved by the current London and Zurich-based teams. The new office in Manchester will open in early 2024.

Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, today announced that Rachi Govil will join the company as Chief Client Officer, Integrated Marketing Communications (IMC). Govil is a healthcare communications veteran with deep experience serving some of the world’s most trusted companies. In her new role, Govil will design and implement innovative approaches to understand client needs and build and grow teams to exceed them. She will partner with leaders across Real Chemistry to continue to deliver impactful work for the company’s outstanding roster of clients.

Real Chemistry, a leading provider of AI-driven insights and marketing and communications for the healthcare industry, today announced a strategic partnership with WhizAI, a leading AI-powered analytics platform purpose-built for life sciences and healthcare. The companies will collaborate on a dynamic patient journey visualization and analytics solution that leverages Real Chemistry’s robust AI and analytics engines. The new offering will make it easy for clients to access accurate, contextual insights and visualize the process patients go through from diagnosis to treatment to better understand access, affordability and adherence to treatments.

Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, announced today the appointment of two senior hires to lead the company’s practices in crisis communications and corporate reputation and social impact. These additions better position Real Chemistry to stay ahead of the needs of its healthcare clients, who are operating in an increasingly complex regulatory, political and social environment and adapting to ever-changing expectations from diverse stakeholders.

Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, today announced a strategic partnership with Writer, the leading generative AI platform for enterprises. Through this partnership, all Real Chemistry team members will have access to Writer, which will allow them to focus on creativity, strategy and innovation in creating content.

Real Chemistry, the leading provider of AI-driven insights and human-centric experiences for the healthcare industry, today reported financial results for the fiscal year ending December 31, 2022. The company achieved revenue of $555 million, reflecting 17% growth compared to $475 million in 2021 and marking the company’s 21st consecutive year of double-digit revenue growth.

Real Chemistry, the leading provider of AI-driven insights and human-centric experiences for the healthcare industry, today announced the acquisition of TI Health, a data-driven marketing and predictive analytics company that delivers omnichannel health care provider (HCP) engagement insights and activation solutions for pharmaceutical and life sciences brands. TI Health will be integrated into Swoop, which is part of Real Chemistry and is the leading provider of exclusive privacy-safe patient audiences, creating a fully unified HCP and direct-to-consumer (DTC) system of engagement for healthcare marketers.

Real Chemistry today provided an update on its business performance during the first half of 2022. The company achieved first half 2022 global revenue of more than $270 million, growth of over 21% compared to the prior year. Real Chemistry is on track to achieve 20% organic growth for the full year compared to 2021. During the first half of 2022, Real Chemistry made significant investments in its data and artificial intelligence (AI) portfolio, commercial and communications service offerings, employee programs and operational infrastructure.

Real Chemistry, a leading global health innovation company committed to making the world a healthier place for all, today announced that Mike Huckman has been appointed to the Biotechnology Innovation Organization (BIO) Board of Directors, effective immediately.

Real Chemistry, a global health innovation company committed to making the world a healthier place for all, today announced the acquisition of conversationHEALTH, the conversational artificial intelligence (AI) platform for the health care and life sciences industry. conversationHEALTH’s HIPAA-compliant and privacy-safe system of engagement utilizes advanced natural language processing, medically-trained natural language understanding and contextual AI to transform conversations into highly-personalized interactions via intelligent agents. The SaaS platform is purpose-built by health care experts and used for scientific communications, medical affairs, clinical trials and commercial operations to enable greater accessibility, improved responsiveness and better outcomes for patients.

Real Chemistry, a global health innovation company committed to making the world a healthier place for all, today announced its 2021 business results. The company achieved revenue of $475 million, reflecting 36% growth for the full year compared to 2020. Last year marked the company’s 20th year of consecutive double-digit revenue growth.

Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the health care sector, today announced that Andy Johnson has joined the company as Chief Information Officer (CIO). Johnson’s primary responsibilities will be to drive Real Chemistry’s information strategy, strengthen organizational systems and processes to best support the company’s people and clients, and innovate new ways to connect and collaborate.

Real Chemistry:

Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the health care sector, today announced that it is now a Veeva Global Content Partner. Veeva Systems is the global leader in cloud software for the life sciences industry, including the majority of Real Chemistry’s customers.

Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the health care sector, today announced Founder and Chief Executive Officer Jim Weiss will become chairman and Shankar Narayanan will become chief executive officer and a member of the board of directors effective January 3, 2022. In addition to his role as chairman and founder of Real Chemistry, Weiss will join New Mountain Capital (NMC), Real Chemistry’s investment partner, as an executive advisor.

Real Chemistry, a leading global health innovation company committed to making the world a healthier place for all, is proud to announce that Jennifer Gottlieb has been appointed to the Ad Council’s Board of Directors. The Ad Council is America’s leading nonprofit organization dedicated to using the power of communications to drive social change and most recently launched the most significant public education effort in U.S. history with the Ad Council and COVID Collaborative’s COVID-19 Vaccine Education Initiative.

Real Chemistry, a global health innovation company committed to making the world a healthier place for all, today provided an update on its business performance during the first half of 2021. The company achieved first half 2021 revenue of more than $200 million and is on track to achieve 35% organic growth for the full year compared to 2020. Company highlights include:

Swoop, the leader in AI-generated digital audiences for healthcare, today announced the release of its newest product offerings that uncover optimal healthcare provider (HCP) influencers for life sciences companies. This first-in-market approach re-imagines HCP targeting in digital advertising beyond conventional National Provider Identifier (NPI) targeting by applying machine learning and artificial intelligence (AI) against a proprietary real-world data universe to uncover HCPs with the highest propensity to be influential brand ambassadors.

Real Chemistry, a global health innovation company, and Aktana, the leader in intelligent customer engagement for the global life sciences industry, today announced a partnership that will transform commercial strategy, engagement and execution. Pre-built integrations between the two companies’ solutions will translate Real Chemistry’s billions of healthcare social data points from 3 million healthcare influencers and 160,000 healthcare providers (HCPs) and claims data into dynamic, actionable insights for life sciences sales, marketing and medical teams.

Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and misdiagnosed patients via artificial intelligence (AI) and machine learning (ML), today announced the release of its newest product offering, which is aimed at revolutionizing patient recruitment for clinical studies of rare and specialty diseases. Life science customers can use The Real Chemistry Clinical Trial Recruitment System to efficiently and effectively find medically-eligible patients within their healthcare ecosystems. This technology-based approach is designed to accelerate clinical investigations and lead to faster patient outcomes with less risk.

Real Chemistry, a global health innovation company committed to making the world a healthier place for all, announced today that Mary Stutts has joined the company to lead its DE&I strategy, bringing together a unique combination of internal inclusion initiatives with multiple customer-facing efforts across the entire health ecosystem. Stutts will further integrate Real Chemistry’s healthcare experts with data and technology to incorporate health equity into the company’s culture, solutions and operations. This appointment integrates and accelerates Real Chemistry’s commitment to DE&I, which expanded last year with the creation of an internal DE&I department led by Marcia Windross and a client engagement practice led by Abby Hayes. Stutts will report directly to the Office of the CEO and the company’s Board of Directors.

Real Chemistry, a global health innovation company committed to making the world a healthier place for all, announced today that Bob Weiler, a seasoned technology executive, and Dr. Amy Grogg, a distinguished market access expert, will join the company’s Board of Directors and CEO Advisory Board, respectively. These appointments will support the company’s growth in these two priority areas as it continues to help customers stay ahead of the increasing consumerization, personalization and digitization happening across the healthcare ecosystem.